DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Bezafibrate
Bezafibrate
Statins and Lipid Lowering Agents
Clinofibrate Improved Canine Lipid Metabolism in Some but Not All Breeds
Effects of Clofibrate Derivatives on Hyperlipidemia Induced by a Cholesterol-Free, High-Fructose Diet in Rats
Bezalip, 200 Mg Film Coated Tablets Bezalip Retard, 400 Mg Sustained Release, Film Coated Tablets
(CPG) for the Management of Dyslipidemia for Cardiovascular
(12) United States Patent (10) Patent No.: US 7,795,310 B2 Lee Et Al
Low Doses of Fenofibrate and Bezafibrate Stimulate Renal 2-Oxoglutarate Dehydrogenase (2-Ogdh) in Protein-Restricted Rats
Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: the Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
PI Changes for Fibrates
Fenofibrate, Bezafibrate, Ciprofibrate and Gemfibrozil Procedure Number
Effect of Low Doses of Bezafibrate and Fenofibrate on Liver 2-Oxoglutarate
Lipid Lowering Drugs Prescription and the Risk of Peripheral Neuropathy
Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
(PPAR) Agonists Activate Hepatitis B Virus Replication in Vivo Lingyao Du, Yuanji Ma, Miao Liu, Libo Yan and Hong Tang*
Review of Existing Classification Efforts
Study Protocol 1002-046 Amendment 1, 10 April 2017
STATIN-FIBRATE REPORT: Focus on Safety VHA Pharmacy Benefits Management-Strategic Healthcare Group and the Medical Advisory Panel
Top View
1. NAME of the MEDICINAL PRODUCT Fluvastatin 20 Mg / 40
Antidiabetic Action of Bezafibrate in a Large Observational Database
Development of a LC-MS/MS Method for the Estimation of Clinofibrate In
Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease
PPAR Agonist Fenofibrate Suppresses Tumor Growth Through Direct
Elucidation of Molecular Mechanism of a Selective PPAR Modulator
Lipid Management in Patients with Endocrine Disorders: an Endocrine
Pharmaceutical Composition Comprising a Combination Of
Prevention of Murine Atherosclerosis with Bempedoic Acid
PPAR-Mediated Toxicology and Applied Pharmacology
Cardiovascular Diabetology Biomed Central
Bezalip and Bezalip Retard CMI
Ezetimibe for Lowering Blood Cholesterol
Package Leaflet: Information for the Patient Fenofibrate 200 Mg
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Fibrates (Fi – Brates)
Bezafibrate Induced Rhabdomyolysis
Lipid Modification to Reduce Cardiovascular Risk
(12) United States Patent (10) Patent No.: US 6,638,969 B1 Keller Et Al
Nilemdo, INN-Bempedoic Acid
Report on Investigation Results
Study Protocol 1002FDC-053 Amendment 1, 18 October 2017
Apolipoprotein a and B (Sf 100-400) Metabolism During Bezafibrate Therapy in Hypertriglyceridemic Subjects
1246 Cardiovascular Drugs
Effect of Bezafibrate on Office, Home and Ambulatory Blood Pressure In
Glutarate Dehydrogenase Complex in Low